Ex Vivo-expanded Autologous T Cells IMA101

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.

**Synonyms:** - ACTolog IMA101 - IMA101 - IMA101 T-Cells - IMA101 T-cell Product